An American patient diagnosed with the coronavirus (COVID-19) has been given a treatment by Israeli-based Pluristem that, so far, has a 100 percent survival rate. The development, which occurred under the Israel’s compassionate-use program, comes days after the company released preliminary data showing that six critically ill coronavirus patients in the Jewish state who are considered high-risk received the Haifa-based company’s placental cell-therapy treatment and survived one week later. The patient, whose condition was similar to the Israeli ones, was treated with Pluristem’s PLX cell therapy at Holy Name Medical Center in New Jersey, where the company is conducting a...